At CPDC we are working with our partners to discover, develop and distribute the next generation of imaging agents and targeted radiotherapeutics for the detection and treatment of human diseases.
VANCOUVER, British Columbia–ARTMS Products Inc., the global leader in the innovation and commercialization of novel technologies that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the appointment of Charles S. Conroy R.Ph, MBA as its Chief Executive Officer. Mr. Conroy brings to ARTMS more than 25 years of experience
Radiopharmaceuticals are a special class of drugs. They’re sometimes called molecular imaging probes, contrast agents, tracers or radiotherapeutics.
Radiopharmaceuticals contain a radioactive isotope and they are used to both diagnose and treat disease. Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures ranging from the assessment of cardiac function to staging and treatment of cancer.
VANCOUVER, British Columbia–ARTMS Products Inc., a global leader in the development and commercialization of novel technologies and products that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce they have received $1.5 million funding from Western Economic Diversification Canada as part of its Business Scale-up and Productivity program. The federal
CPDC is always looking for exceptional people to strengthen our team.
